Uncategorized
Good results seen in phase 3 trial of tocilizumab in giant cell arteritis
Tocilizumab was shown to have a statistically significant inhibiting effect on IL-6, which is known to be elevated in patients with giant cell arteritis, according to the results of a phase 3 study presented at the North American Neuro-Ophthalmology Society annual meeting. “The results of Genentech’s GiACTA trial are encouraging for GCA patients and the physicians who treat them,” Philip R. Rizzuto, MD, FACS, clinical associate professor of ophthalmic surgery at Brown University, Warren Alpert Medical School, said in correspondence from Genentech. “Long-term, high-dose steroid use can be problematic for (Read more...)